Literature DB >> 2160976

Preparation of biologically active 32P-labeled human relaxin. Displaceable binding to rat uterus, cervix, and brain.

P L Osheroff1, V T Ling, R L Vandlen, M J Cronin, J A Lofgren.   

Abstract

Relaxin is a member of the insulin family of polypeptide hormones and is known to exert its biological effects on various parts of the mammalian reproductive system. Biologically active human relaxin has been chemically synthesized based on the nucleotide sequence obtained from an ovarian cDNA clone. In the present study synthetic human relaxin was radiolabled by phosphorylation with cAMP-dependent protein kinase and [gamma-32P]ATP to a specific activity of 5000 Ci/mmol. The phosphorylated relaxin was purified on cation exchange high performance liquid chromatography and was shown to co-migrate with relaxin on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Mass spectrometry revealed a single phosphorylated site on the B chain of relaxin. The 32P-relaxin was able to bind to a goat anti-relaxin antibody, and this binding could be displaced by unlabeled relaxin in a concentration-dependent manner. A comparison of the concentration responses of cellular cAMP production stimulated by relaxin and phosphorylated relaxin in a primary human uterine cell line showed that phosphorylation did not affect the in vitro biological efficacy of relaxin. This made it suitable for in situ autoradiographic localization of relaxin binding sites in rat uterine, cervical, and brain tissue sections. Displacement of the binding of 100 pM 32P-relaxin by 100, 10, and 3 nM unlabeled relaxin, but not by 100 nM insulin, insulin-like growth factor-I, and an insulin-like growth factor-I analog, demonstrated the high affinity and specificity of such binding. We conclude that 32P-labeled human relaxin is biologically and immunologically active and that this novel probe binds reversibly and with high affinity to classical (e.g. uterus) and unpredicted (e.g. brain) tissues.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2160976

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 2.  Relaxin family peptide systems and the central nervous system.

Authors:  G E Callander; R A D Bathgate
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

3.  Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: characterization and effects of oestrogen treatment.

Authors:  Y Y Tan; J D Wade; G W Tregear; R J Summers
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

4.  Central administration of porcine relaxin stimulates drinking behaviour in rats: an effect mediated by central angiotensin II.

Authors:  A J Summerlee; G F Robertson
Journal:  Endocrine       Date:  1995-05       Impact factor: 3.633

5.  Autoradiographic localization of relaxin binding sites in rat brain.

Authors:  P L Osheroff; H S Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

6.  Primate relaxin: synthesis of gorilla and rhesus monkey relaxins.

Authors:  J D Wade; S S Layden; P F Lambert; H Kakouris; G W Tregear
Journal:  J Protein Chem       Date:  1994-04

7.  Relaxin binding in the rat heart atrium.

Authors:  P L Osheroff; M J Cronin; J A Lofgren
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

8.  The cardiovascular effects of porcine relaxin in Brattleboro rats.

Authors:  L J Parry; B C Wilson; R S Poterski; A J Summerlee
Journal:  Endocrine       Date:  1998-06       Impact factor: 3.925

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.